Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy.

Molecular cancer therapeutics - 1 Oct 2011

Kim Seung Tae, Lim Do Hyoung, Jang Kee-Taek, Lim Taekyu, Lee Jeeyun, Choi Yoon-La, Jang Hye-Lim, Yi Jun Ho, Baek Kyung Kee, Park Se Hoon, Park Young Suk, Lim Ho Yeong, Kang Won Ki, Park Joon Oh

Abstract excerpt

Although erlotinib has become an important therapeutic option in addition to gemcitabine, the high frequency of KRAS mutations in pancreatic cancer probably limits the benefits. We retrospectively studied 136 pancreatic cancer patients with available formalin-fixed paraffin-embedded tumor blocks from 2003 to 2009 to understand the clinical significance of KRAS mutations in pancreatic cancer patients treated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Erlotinib Hydrochloride

Share to Gemcitabine

Share to Genes, ras

Share to Pancreatic Neoplasms

Share to Quinazolines

Source

Identifiers

PMID: 21862683
DOI: 10.1158/1535-7163.MCT-11-0269

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy.PMID 21862683Read ↗

Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.Semantic proximity Read ↗

Somatic Mutations in Exocrine Pancreatic Tumors: Association with Patient SurvivalSemantic proximity Read ↗

EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer.Semantic proximity Read ↗

Impact of KRAS Mutations and Co-mutations on Clinical Outcome in Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Prognostic value of KRAS gene mutations in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.Semantic proximity Read ↗

KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer.Semantic proximity Read ↗

KRAS mutation in pancreatic cancer.Semantic proximity Read ↗

KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.Semantic proximity Read ↗

Prognostic Properties of KRAS Gene Mutation Subtypes in Resected Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Prognostic Implications of Codon-Specific KRAS Mutations in Localized and Advanced Stages of Pancreatic Cancer.Semantic proximity Read ↗

Precision medicine for KRAS wild-type pancreatic adenocarcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.